ABACAVIR/LAMIVUDINE LAPL 600/300 abacavir (as hydrochloride) 600 mg and lamivudine 300 mg film-coated tablet bottle pack

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

lamivudine, Quantity: 300 mg; abacavir hydrochloride monohydrate, Quantity: 714.162 mg (Equivalent: abacavir, Qty 600 mg)

Disponibbli minn:

Lupin Australia Pty Limited

INN (Isem Internazzjonali):

abacavir hydrochloride monohydrate,Lamivudine

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow FCF; polysorbate 80; macrogol 400

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

30 tablets (HDPE bottle with PP child-resistant closure)

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

ABACAVIR/LAMIVUDINE LAPL is a combination of two nucleoside analogues (abacavir and lamivudine). ABACAVIR/LAMIVUDINE LAPL is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.

Sommarju tal-prodott:

Visual Identification: Orange coloured, modified capsule shaped, biconvex, film-coated tablets debossed with 300 on one side and 600 on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2017-10-06